[{"id":"a7c4f9e4-84af-4d2b-9a47-edc69ca3a38e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476729","created_at":"2026-03-28T01:40:41.936Z","updated_at":"2026-03-28T01:40:41.936Z","phase":"Phase 3","brief_title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","source_id_and_acronym":"NCT07476729","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2026-03-17"},{"id":"5d8be821-57f9-4a69-b151-4d28ee8d8c8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472517","created_at":"2026-03-28T01:39:51.238Z","updated_at":"2026-03-28T01:39:51.238Z","phase":"Phase 3","brief_title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","source_id_and_acronym":"NCT07472517","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 670","initiation":"Initiation: 04/10/2026","start_date":" 04/10/2026","primary_txt":" Primary completion: 09/10/2028","primary_completion_date":" 09/10/2028","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2026-03-16"},{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"a4247f5e-b84a-4f2b-a095-1fca8e76f331","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905509","created_at":"2025-08-02T14:06:01.421Z","updated_at":"2025-08-02T14:06:01.421Z","phase":"Phase 2","brief_title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT06905509","lead_sponsor":"University of California, Davis","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-04-01"},{"id":"ac4afb38-f9f0-4fe8-a6ec-8ae6a59cd318","acronym":"A041703","url":"https://clinicaltrials.gov/study/NCT03739814","created_at":"2021-01-18T18:19:08.468Z","updated_at":"2025-02-25T12:27:03.899Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03739814 - A041703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 positive","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-24"},{"id":"736082c4-cb8f-4038-ae24-2c9486718043","acronym":"BP41072","url":"https://clinicaltrials.gov/study/NCT04077723","created_at":"2021-01-18T19:58:08.759Z","updated_at":"2025-02-25T13:39:56.985Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04077723 - BP41072","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-21"},{"id":"a744dd9f-e4be-4b72-a2de-da79e8056978","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800964","created_at":"2023-04-06T14:03:12.774Z","updated_at":"2025-02-25T13:55:05.180Z","phase":"Phase 1","brief_title":"Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05800964","lead_sponsor":"Amgen","biomarkers":" MSLN • CDH3","pipe":"","alterations":" ","tags":["MSLN • CDH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 305"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 06/10/2027","primary_completion_date":" 06/10/2027","study_txt":" Completion: 02/12/2028","study_completion_date":" 02/12/2028","last_update_posted":"2025-02-20"},{"id":"e8b91e71-29e4-4b49-a8d1-038d6c000854","acronym":"HPN328-4001","url":"https://clinicaltrials.gov/study/NCT04471727","created_at":"2021-01-18T21:29:07.037Z","updated_at":"2025-02-25T12:37:38.530Z","phase":"Phase 1/2","brief_title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","source_id_and_acronym":"NCT04471727 - HPN328-4001","lead_sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck \u0026 Co., Inc. (Rahway, New Jersey USA)","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)"],"overall_status":"Recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-20"},{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"4ba4b07b-a4a4-4a2f-83be-8b39ce10d97d","acronym":"OLYMPIA-1","url":"https://clinicaltrials.gov/study/NCT06091254","created_at":"2023-10-19T17:13:09.646Z","updated_at":"2025-02-25T14:03:56.559Z","phase":"Phase 3","brief_title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma","source_id_and_acronym":"NCT06091254 - OLYMPIA-1","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Ordspono (odronextamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 04/04/2029","primary_completion_date":" 04/04/2029","study_txt":" Completion: 04/04/2029","study_completion_date":" 04/04/2029","last_update_posted":"2025-02-19"},{"id":"48a9756f-4a13-44e2-87fd-34412cf0be4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990738","created_at":"2023-08-14T14:10:29.956Z","updated_at":"2025-02-25T14:09:58.704Z","phase":"Phase 1","brief_title":"DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","source_id_and_acronym":"NCT05990738","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan • obrixtamig (BI 764532)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 11/21/2026","study_completion_date":" 11/21/2026","last_update_posted":"2025-02-18"},{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"dc690118-6ca4-4812-9ba9-2f56494fb793","acronym":"GO29781","url":"https://clinicaltrials.gov/study/NCT02500407","created_at":"2021-01-18T12:03:14.142Z","updated_at":"2025-02-25T14:06:51.320Z","phase":"Phase 1/2","brief_title":"A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","source_id_and_acronym":"NCT02500407 - GO29781","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 713","initiation":"Initiation: 09/15/2015","start_date":" 09/15/2015","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-18"},{"id":"652fcefb-b53c-4b62-8b35-ac9d0a1fa74e","acronym":"SKYGLO","url":"https://clinicaltrials.gov/study/NCT06047080","created_at":"2023-09-21T14:10:31.989Z","updated_at":"2025-02-25T14:18:19.180Z","phase":"Phase 3","brief_title":"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","source_id_and_acronym":"NCT06047080 - SKYGLO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 1130","initiation":"Initiation: 09/18/2023","start_date":" 09/18/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2025-02-17"},{"id":"65a39e57-0fe4-43a3-8e14-9aae8f76d3a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06124157","created_at":"2023-11-09T16:12:44.229Z","updated_at":"2025-02-25T14:42:30.057Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT06124157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-02-14"},{"id":"f3d0b4ce-a825-4e88-abe6-0a2852f91550","acronym":"SUNMO","url":"https://clinicaltrials.gov/study/NCT05171647","created_at":"2021-12-29T14:53:50.426Z","updated_at":"2025-02-25T14:41:08.199Z","phase":"Phase 3","brief_title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05171647 - SUNMO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Actemra IV (tocilizumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-14"},{"id":"66a34534-4876-4aef-b0bc-743d3e1fef57","acronym":"OLYMPIA-2","url":"https://clinicaltrials.gov/study/NCT06097364","created_at":"2023-10-24T15:13:48.813Z","updated_at":"2025-02-25T15:20:58.496Z","phase":"Phase 3","brief_title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","source_id_and_acronym":"NCT06097364 - OLYMPIA-2","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ordspono (odronextamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 733","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/29/2029","primary_completion_date":" 07/29/2029","study_txt":" Completion: 07/29/2029","study_completion_date":" 07/29/2029","last_update_posted":"2025-02-12"},{"id":"8e3b627a-4aef-4d49-a1cb-f09137cdb6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06536049","created_at":"2025-02-25T15:21:55.068Z","updated_at":"2025-02-25T15:21:55.068Z","phase":"Phase 1/2","brief_title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06536049","lead_sponsor":"Yazeed Sawalha","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Epkinly (epcoritamab-bysp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"0a2b6dbc-36dd-467c-bb46-4e7fcb611199","acronym":"CO41942","url":"https://clinicaltrials.gov/study/NCT04246086","created_at":"2023-03-27T23:03:02.854Z","updated_at":"2025-02-25T15:34:35.235Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","source_id_and_acronym":"NCT04246086 - CO41942","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2030","study_completion_date":" 10/15/2030","last_update_posted":"2025-02-10"},{"id":"2dc4eb4c-eda6-4d7f-bf25-c974b4ee8106","acronym":"CO43805","url":"https://clinicaltrials.gov/study/NCT05169515","created_at":"2021-12-27T15:54:16.180Z","updated_at":"2025-02-25T15:27:09.973Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05169515 - CO43805","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb) • iberdomide (CC-220) • Columvi (glofitamab-gxbm) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 03/07/2027","primary_completion_date":" 03/07/2027","study_txt":" Completion: 03/07/2029","study_completion_date":" 03/07/2029","last_update_posted":"2025-02-10"},{"id":"41da52dc-40c3-45b4-8b73-2f7fc868f90a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04468607","created_at":"2021-01-18T21:28:24.971Z","updated_at":"2025-02-25T15:26:25.899Z","phase":"Phase 1","brief_title":"A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04468607","lead_sponsor":"Genentech, Inc.","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e linclatamig (RG6286)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 10/16/2024","primary_completion_date":" 10/16/2024","study_txt":" Completion: 10/16/2024","study_completion_date":" 10/16/2024","last_update_posted":"2025-02-10"},{"id":"dba621d0-4a3a-4b6c-9b33-c48c7ade782a","acronym":"iMATRIX GLO","url":"https://clinicaltrials.gov/study/NCT05533775","created_at":"2022-09-09T15:55:02.207Z","updated_at":"2025-02-25T15:27:37.954Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05533775 - iMATRIX GLO","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • Gazyva (obinutuzumab) • ifosfamide • etoposide IV • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 03/30/2027","primary_completion_date":" 03/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2025-02-10"},{"id":"33ca6a18-d45b-42c8-9bb0-e546b4b79d4d","acronym":"GLOBRYTE","url":"https://clinicaltrials.gov/study/NCT06084936","created_at":"2023-10-16T15:12:59.101Z","updated_at":"2025-02-25T16:33:44.879Z","phase":"Phase 3","brief_title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT06084936 - GLOBRYTE","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 10/22/2023","start_date":" 10/22/2023","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-07"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"}]